The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients
NCT ID: NCT05429554
Last Updated: 2022-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2022-06-30
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metformin Versus Vildagliptin for Diabetic Hypertensive Patients
NCT03253562
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
NCT04485845
Cognitive Protective Effect of Newer Antidiabetic Drugs
NCT05347459
Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes
NCT04916093
Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients
NCT06068686
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to compare between the cardiovascular protective properties of DPP-4 inhibitors and Metformin in type 2 diabetic patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
patients will be treated with DPP4 inhibitor + metformin
Vildagliptin
observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
control
patients will be treated with metformin without DPP4 inhibitor.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vildagliptin
observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* moderate hypertension.
Exclusion Criteria
* Patients with type 1 DM, active liver disease, recent history of cardiovascular disease (acute coronary syndrome, coronary artery intervention, New York Heart Association Class III/IV heart failure, stroke, transient ischemic neurologic event, or new/worsening symptoms of coronary heart disease or cerebrovascular disease), severe peripheral vascular disease, triglyceride levels ≥ 600 mg/dL, history of HIV infection, pancreatitis, malignancy or clinically important hematologic disorder, and an estimated glomerular filtration rate (eGFR; calculated using the Modification of Diet in Renal Disease formula) less than 30 mL/min/1.73 m2.
* Moreover, patients with dementia, AD, those were in delirium status during evaluation period, patients with psychotic disease (schizoaffective disorder, etc.)
* Alcohol and substance addiction were not enrolled in the study.
* Also, patients who have any hypersensitivity to metformin or to DPP4 inhibitors were also excluded.
40 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Endocrinology, Egypt
UNKNOWN
MTI University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Toka Hesham
Teaching assistant of Clinical Pharmacy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toka Hesham
Role: PRINCIPAL_INVESTIGATOR
Bachelor of Pharmacy and Pharmaceutical sciences (Clinical Pharmacy)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of diabetes and endocrinology
Cairo, Al Kasr Al Aini, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDEoo281
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.